Simplified Chinese
Kangtai Biological: Tackling the Global Challenge of Antibiotic-Resistant “Superbugs” by Pioneering Innovative Vaccine R&D Worldwide
Release date:
2025-08-29
Author:
Source:
Abstract
Recently, Shenzhen Kangtai Biological Products Co., Ltd. has launched a research and development project for a globally innovative vaccine—Pneumonia Klebsiella vaccine—and will vigorously advance the preclinical studies, clinical trials, and subsequent industrialization of this vaccine.
Klebsiella pneumoniae is currently one of the most drug‑resistant and virulent bacteria in clinical practice, often referred to as the “king of superbugs.” In particular, carbapenem‑resistant Klebsiella pneumoniae (CRKP) exhibits resistance to virtually all first‑ and second‑line antibiotics. 2024 The 12th National Survey Report on the Prevalence of Hospital-Acquired Infections indicates that Klebsiella pneumoniae is the most frequently detected pathogen. In the World Health Organization’s “2024 Priority List of Bacterial Pathogens,” carbapenem‑resistant Klebsiella pneumoniae has been designated as a critical priority, making it one of the pressing global public health challenges that urgently require effective solutions.
This Klebsiella pneumoniae vaccine is a globally original, first‑in‑class product. Developed using cutting‑edge technologies such as reverse vaccinology and synthetic biology, it is a novel recombinant multivalent combination vaccine. To date, it has completed drug‑development studies and preliminary safety assessments. In animal models of pneumonia, its challenge‑protection rate remains consistently above 80%, demonstrating excellent efficacy and broad‑spectrum coverage. This vaccine is indicated for global use in high-risk populations for Klebsiella pneumoniae infection, including hospitalized patients undergoing prolonged hospitalization, invasive intensive care, or abdominal or urological surgery—particularly those at risk of surgical-site or device‑related infections—as well as healthcare workers, individuals with diabetes, patients with chronic respiratory diseases such as COPD, and vulnerable groups like infants and the elderly. Relevant data indicate that China sees over 50 million inpatient surgical procedures annually, with more than 100 million people living with diabetes and approximately 100 million with COPD. Globally, the number of individuals affected by diabetes and COPD exceeds 800 million and 600 million, respectively, underscoring substantial market potential.
To date, no vaccine of this type has yet been approved for market launch worldwide. The successful implementation of this project is expected to fill a critical gap in national new‑drug development, and it holds significant strategic importance for strengthening China’s vaccine R&D platform and advancing the high‑quality development of the nation’s greater health industry. Moreover, by fostering integrated innovation among industry, academia, and research institutions, it may offer a “Chinese solution” to the global challenge of antibiotic resistance.
Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account